m<sup>6</sup>A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC.

Jin D, Guo J, Wu Y, Yang L, Wang X, Du J, Dai J, Chen W, Gong K, Miao S, Li X, Sun H. · 2020

Read m<sup>6</sup>A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC. by Jin D, Guo J, Wu Y, Yang L, Wang X, Du J, Dai J, Chen W, Gong K, Miao S, Li X, Sun H. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7045432.txt.

Introduction

Jin and co-authors untangle an RNA control circuit in lung cancer in Molecular Cancer. ALKBH5 is an enzyme that erases m6A marks from RNA. YAP is a growth driver switched on in many cancers. How ALKBH5 might govern YAP in non-small cell lung cancer, and with what effect on tumours, had not been worked out.

YAP levels moved opposite to ALKBH5 across the cell systems tested. ALKBH5 stripped m6A marks from YAP RNA, changing how reader proteins handled it. One reader, YTHDF3, bound the RNA; YTHDF1 then promoted its translation while YTHDF2 pushed its decay through the AGO2 system. ALKBH5 also acted through a microRNA route involving miR-107 and LATS2 to restrain YAP activity. The net effect: ALKBH5 slowed tumour growth and metastasis. The circuit suggests restoring this eraser could rein in aggressive lung cancers.

Catalog record

CREATORJin D, Guo J, Wu Y, Yang L, Wang X, Du J, Dai J, Chen W, Gong K, Miao S, Li X, Sun H.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE102 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7045432

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC By Dan Jin, Jiwei Guo, Yan Wu, Lijuan Yang, Xiaohong Wang, Jing Du, Juanjuan Dai, Weiwei Chen, Kaikai Gong, Shuang Miao, Xuelin Li, Hongliang Sun Published in: Molecular Cancer DOI: 10.1186/s12943-020-01161-1 ABSTRACT Abstract Background The importance of mRNA methylation erased by ALKBH5 in mRNA biogenesis, decay, and translation control is an emerging research focus. Ectopically activated YAP is associated with the development of many human cancers. However, the mechanism whereby ALKBH5 regulates YAP expression and activity to inhibit NSCLC tumor growth and metastasis is not clear. Methods Protein and transcript interactions were analyzed in normal lung cell and NSCLC cells. Gene expression was evaluated by qPCR and reporter assays. Protein levels were determined by immunochemical approaches. Nucleic acid interactions and status were analyzed by immunoprecipitation. Cell behavior was analyzed by standard biochemical tests. The m6A modification was analyzed by MeRIP. Results Our results show that YAP expression is negatively correlated with ALKBH5 expression and plays an opposite role in the regulation of cellular proliferation, invasion, migration, and EMT of NSCLC cells. ALKBH5 reduced m6A modification of YAP. YTHDF3 combined YAP pre-mRNA depending on m6A modification. YTHDF1 and YTHDF2 competitively interacted with YTHDF3 in an m6A-independent manner to regulate YAP expression. YTHDF2 facilitated YAP mRNA decay via the AGO2 system, whereas YTHDF1 promoted YAP mRNA translation by interacting with eIF3a; both these activities are regulated by m6A modification. Furthermore, ALKBH5 decreased YAP activity by regulating miR-107/LATS2 axis in an HuR-dependent manner. Further, ALKBH5 inhibited tumor growth and metastasis in vivo by reducing the expression and activity of YAP. Conclusions The presented findings suggest m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC. Moreover, effective inhibition of m6A modification of ALKBH5 might constitute a potential treatment strategy for lung cancer. Keywords: ALKBH5, YTHDFs, HuR, miR-107, LATS2, YAP BACKGROUND Non-small cell lung cancer (NSCLC) is a highly malignant tumor, with high clinical incidence and mortality that annually increase globally [1]. Even when individuals with NSCLC are treated with a combination of surgery and chemotherapy, the survival rate is low because of cancer cell metastasis and invasion [2]. Therefore, finding an effective target to inhibit cancer cell growth and invasion in NSCLC is urgently needed. More than 100 chemical modifications of cellular RNA are known. Reversible RNA modification constitutes a new level of post-transcriptional regulation of gene expression, involved in many physiological processes and with multiple biological roles [3]. N6-methyladenine (m6A) is a dynamic reversible chemical modification. It is the most abundant internal modification of mRNA and a new transcription marker. In mammals, plants, and some prokaryotes, m6A is widely involved in mRNA metabolism, affecting mRNA stability and splicing, RNA nucleation, RNA-protein interaction, and mRNA translation [4, 5]. The enzymes m6A demethylases are also known as “erasers”. Two eukaryotic m6A demethylases have been identified to date: fat mass and obesity-associated protein (FTO) and AlkB homolog 5 (ALKHB5). ALKHB5 is a member of the AlkB family, which plays an important role in regulation of many biological processes, such as mRNA processing [6]. According to recent studies, ALKBH5 plays an important role in the occurrence and development of cancer in human [6, 7]. For example, ALKBH5 holds prognostic value and inhibits the metastasis of colon cancer [8]; ALKBH5 controls trophoblast invasion at the maternal-fetal interface by regulating the stability of Cyr61 mRNA [9]; METTL3 and ALKBH5 oppositely regulate m6A modification of TFEB mRNA, dictating the fate of hypoxia/reoxygenation-treated cardiomyocyte [10]; ALKBH5 inhibits pancreatic cancer cell motility by decreasing methylation of the long non-coding RNA KCNK15-AS1 [11]. Moreover, HuR restrains translation inhibition mediated by some miRNAs by directly binding and sequestering microRNAs (miRNAs). In addition, studies have shown that m6A indirectly impacts transcript stability, by affecting HuR binding and microRNA targeting [12, 13]. However, the mechanism through which ALKBH5 regulates NSCLC tumor growth and metastasis is not clear. A group of YTH domain-containing proteins (YTHDFs) have been identified as m6A “readers” that recognize m6A marks and mediate m6A function [14]. The human YTH domain family consists of three members: YTHDF1–3. Each member contains a highly conserved single-stranded RNA-binding domain, located at their carboxyl termini (the YTH domain) and a relatively less conserved amino-terminal region [15]. YTHDF1 improves the translation efficiency by binding to m6A-modified mRNA [16], whereas YTHDF2 reduces the stability of mRNA by recruiting an mRNA degradation system [17]. YTHDF3 serves as a hub to fine-tune the accessibility of RNA to YTHDF1 and YTHDF2. YTHDFs have many important biological functions [18]. For instance, YTHDF3 suppresses interferon-dependent antiviral responses by promoting FOXO3 translation in HREpiC cells [19] and YTHDF2 promotes lung cancer cell growth by facilitating translation of 6-phosphogluconate dehydrogenase mRNA [20]. However, the manner in which YTHDF3 cooperates with YTHDF1 and YTHDF2 to promote the translation or decay of m6A-modified YAP mRNA in NSCLC remains to be elucidated. MicroRNAs (miRNAs) are a group of non-coding single-stranded RNA molecules 20–24 nucleotides-long, encoded by endogenous genes. miRNA interacts with a specific mRNA, triggering its degradation, inhibiting translation and widely participating in the organism growth, development, differentiation, metabolism, defenses, and other processes [21]. Significant differences in the expression of various miRNAs in healthy cells and tumor cells have been recently reported. These miRNAs play a role similar to that of proto-oncogenes or tumor suppressor genes, by regulating different target genes, and are closely related to the occurrence, development, treatment, and prognosis of tumors in human [22]. The Hippo signaling pathway is an inhibitory pathway that hinders cell growth and controls cell proliferation, organ size, and homeostasis [23]. This pathway is highly evolutionarily conserved. The main components of the mammalian pathway are Mst1/2, LATS1/2, and Yap/TAZ. After activation of the Hippo signaling pathway, Mst1/2, as the core component of this kinase chain, is activated and phosphorylates a downstream component of LATS1/2. LATS1/2 mainly inhibits the proliferation and migration of tumor cells by blocking cell cycle progression and plays an important regulatory role in cell apoptosis. LATS1/2 phosphorylates Yap/TAZ, which inhibits YAP activity; then, cytoplasmic 14–3-3 protein binds phosphorylated Yap to promote YAP degradation. Dephosphorylated Yap/TAZ translocate to the nucleus, where it binds tea domain family members (TEADs) to promotes target gene transcription. The target genes include Ctgf, Cyr61, Oct4, p73, and ZEB1, and control organ size, tumor cell proliferation, and metastasis [24]. However, the transcriptional regulation of the Hippo signaling pathway, especially following YAP transcription modified by m6A, has not yet been delineated. We here aimed to explore the mechanism whereby ALKBH5 inhibits tumor growth and metastasis by regulating the expression and activity of YAP in NSCLC. Using lung healthy cells and tumor cells, we demonstrated the following: (1) ALKBH5 decreases the level of m6A YAP mRNA modification; (2) YTHDF1 and YTHDF2 competitively bind YTHDF3 in an m6A-independent manner to regulate YAP expression; (3) YTHDF2 facilitates the decay of YAP mRNA, which is mediated by Argonaute 2 (AGO2) system and regulated by m6A modification; (4) YTHDF1 promotes m6A modification-mediated YAP mRNA translation via interaction with eIF3a; (5) ALKBH5 decreases the activity of YAP by regulating the miR-107/LATS2 axis in an HuR-dependent manner. These findings clarify the role of m6A

Read the complete text